BD PharmingenTM PE Rat Anti-Human IL-2

Description

Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel . Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel . Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel . Show More Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel . Show More Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel . Expression of IL-2 by stimulated CD3+ and CD3-human PBMC. Human PBMC were stimulated for 18 hours with PMA Sigma, Cat. No. P-8139 and ionomycin Sigma, Cat. No. I-0634 , in the presence of BD GolgiStop 2 mul final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 20 mul of the PE Rat Anti-Human IL-2 antibody Cat. No. 560902/559334/554566; left panel . To demonstrate specificity of staining, the binding of PE-MQ1-17H12 was blocked by the preincubation of the conjugated antibody with recombinant human IL-2 0.25 mg, Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with an excess of Purified Rat Anti-Human IL-2 10 mg, Cat. No. 554563; right panel prior to staining with the PE-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking specificity controls right panel .